Workplace & School Programs
Population-level prevention requires institutional support with growing evidence base. The session covers workplace wellness ROI and the meta-analyses challenging earlier claims, school nutrition standards (US Smarter Lunchrooms, EU School Fruit Scheme), employer-sponsored GLP-1 access and the cost-management debate, cafeteria and vending interventions, physical-education evidence, and built-environment interventions. Discussion addresses corporate weight-loss programmes (Weight Watchers Wellness vs employer-direct GLP-1), the stigma considerations in workplace weight-management, school-based screening vs intervention, the comparison of US vs European approaches to school nutrition, and the policy levers including sugar-sweetened-beverage taxes.
- Workplace wellness ROI
- School nutrition standards
- Employer GLP-1 access
- Cafeteria interventions
- Physical-education evidence
- Built-environment interventions
- Workplace weight stigma
- Sugar-sweetened beverage taxes
Explore the full GSOD 2027 program
- 01GLP-1 & Incretin Therapies
- 02Bariatric Surgery
- 03Childhood & Adolescent Obesity
- 04Obesity Genetics & Epigenetics
- 05Metabolic Syndrome
- 06Behavioral & Lifestyle Interventions
- 07Gut Microbiome & Metabolism
- 08Health Equity in Obesity Care
- 09Policy, Environment & Prevention
- 10Weight Loss Maintenance
- 11Eating Disorders & Obesity
- 12Sarcopenic Obesity
- 13Hormonal Drivers
- 14Cardiometabolic Complications
- 15MASH & Obesity-Liver Axis
- 16Sleep & Obesity
- 18Pharmacotherapy Pipeline
- 19Type 1 Diabetes
- 20Type 2 Diabetes
- 21Diabetic Retinopathy
- 22Diabetic Neuropathy
- 23Diabetic Kidney Disease
- 24Polycystic Ovary Syndrome
- 25Thyroid & Weight
- 26Insulin Resistance
- 27Lipid Metabolism
- 28Body Composition
- 29Body Image & Mental Health
- 30Diabetes in Pregnancy
- 31Telemedicine in Obesity
- 32Endocrine Disruptors
- 33Health Coaching
- 34Geriatric Obesity
- 35Stigma & Communication